Details of the Drug Reposition

General Information of This Drug (ID: DML4BT1)

Drug Name
Eftilagimod alpha   DML4BT1
Synonyms IMP321
Drug Type
Recombinant?protein

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [1]
Squamous head and neck cell carcinom DIS0UVDG 2D60.0 Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03625323) Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002). U.S. National Institutes of Health.